Contact Us
Careers
SHARE

Press Releases

May 19, 2022
Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Cells Derived from Healthy, Younger Donors were More Abundant with Greater Fitness and Cancer Killing Potential Than Cells Derived from Patients with Cancer Findings Underscore Potential of Allogeneic CAR T Products to Improve Patient Outcomes SOUTH SAN FRANCISCO, Calif.
May 04, 2022
Allogene Therapeutics Reports First Quarter 2022 Financial Results
Pivotal Phase 2 ALPHA2 Trial of ALLO-501A in R/R Large B Cell Lymphoma Planned to Commence Mid 2022 Using Product from Cell Forge 1 (CF1) CF1 is Projected to Support the Manufacture of ~20,000 Doses of AlloCAR T™ Products Annually at Scale Clinical Updates from the CD19 and BCMA Programs Planned
Apr 28, 2022
Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer
New Position Aimed at Attracting, Retaining, and Cultivating a Best-in-Class Workforce as Allogene Scales its Operations for its Next Stage of Growth SOUTH SAN FRANCISCO, Calif. , April 28, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company
Apr 13, 2022
Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal
Data Continue to Highlight the Potential of ALLO-316 to Treat Both Solid Tumors and Hematologic Malignancies ALLO-316, in Phase 1 TRAVERSE Trial for the Treatment of Renal Cell Carcinoma, Granted Fast Track Designation (FTD) by the U.S. FDA in March 2022 SOUTH SAN FRANCISCO, Calif.
Displaying 1 - 10 of 19
Print Page
Print Page
Email Alerts
Email Alerts
RSS Feeds
RSS Feeds
Investor Contacts
Investor Contacts
TERMS OF USE
PRIVACY POLICY